Overcoming platinum resistance in ovarian carcinoma

Bibliography

• Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Omura G, Blessing JA, Ehrlich CE, A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 1986;57:1725-30
   PubMed Web of Science ®Google Scholar
• Matsuo K, Bond VK, Eno ML, Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int J Cancer 2009;125:2721-7
   PubMed Web of Science ®Google Scholar
• Matsuo K, Eno ML, Im DD, Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol 2010;116:61-5
   PubMed Web of Science ®Google Scholar
• Markman M, Rothman R, Hakes T, Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93
   PubMed Web of Science ®Google Scholar
• Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990;36:207-11
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Powell MA, Rader JS, Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol 2008;111:467-73
   PubMed Web of Science ®Google Scholar
• Peters GJ, Van Moorsel CJ, Lakerveld B, Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int J Oncol 2006;28:237-44
   PubMed Web of Science ®Google Scholar
• Wynne P, Newton C, Ledermann JA, Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 2007;97:927-33
   PubMed Web of Science ®Google Scholar
• van Moorsel CJ, Pinedo HM, Veerman G, Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999;80:981-90
   PubMed Web of Science ®Google Scholar
• Mutch DG, Orlando M, Goss T, Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:2811-18
   PubMed Web of Science ®Google Scholar
• Galligioni E, Arcuri C, Sorio R, Griso C. Gemcitabine and anthracyclines in platinum-resistant ovarian cancer. Ann Oncol 2006;17(Suppl 5):v195-8
   PubMed Web of Science ®Google Scholar
• Pectasides D, Xiros N, Papaxoinis G, Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma. Gynecol Oncol 2008;108:47-52
   PubMed Web of Science ®Google Scholar
• Petru E, Angleitner-Boubenizek L, Reinthaller A, Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. Gynecol Oncol 2006;102:226-9
   PubMed Web of Science ®Google Scholar
• Skarlos DV, Kalofonos HP, Fountzilas G, Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Anticancer Res 2005;25:3103-8
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Weber B, Cretin J, Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer 2009;100:601-7
   PubMed Web of Science ®Google Scholar
• Harnett P, Buck M, Beale P, Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer 2007;17:359-66
   PubMed Web of Science ®Google Scholar
• Bozas G, Bamias A, Koutsoukou V, Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol 2007;104:580-5
   PubMed Web of Science ®Google Scholar
• Brewer CA, Blessing JA, Nagourney RA, Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006;103:446-50
   PubMed Web of Science ®Google Scholar
• Goff BA, Holmberg LA, Veljovich D, Kurland BF. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium. Gynecol Oncol 2008;110:146-51
   PubMed Web of Science ®Google Scholar
• Greggi S, Salerno MG, D'Agostino G, Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology 2001;60:19-23
   PubMed Web of Science ®Google Scholar
• Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54(Suppl 4):15-21
   PubMed Web of Science ®Google Scholar
• Strauss HG, Hemsen A, Karbe I, Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anticancer Drugs 2008;19:541-5
   PubMed Web of Science ®Google Scholar
• Chou HH, Wang KL, Chen CA, Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol Oncol 2006;101:423-8
   PubMed Web of Science ®Google Scholar
• Verhaar-Langereis M, Karakus A, van Eijkeren M, Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. Int J Gynecol Cancer 2006;16:65-70
   PubMed Web of Science ®Google Scholar
• Rose PG, Smrekar M, Haba P, A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer. Am J Clin Oncol 2008;31:476-80
   PubMed Web of Science ®Google Scholar
• Sood AK, Lush R, Geisler JP, Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res 2004;10:6080-5
   PubMed Web of Science ®Google Scholar
• Zwelling LA, Kohn KW. Mechanism of action of cis-dichlorodiammineplatinum(II). Cancer Treat Rep 1979;63:1439-44
   PubMedGoogle Scholar
• Polyzos A, Kosmas C, Tsavaris N, Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel. Anticancer Res 2007;27:1645-51
   PubMed Web of Science ®Google Scholar
• Morgan RJ Jr, Synold TW, Gandara D, Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. Int J Gynecol Cancer 2007;17:373-8
   PubMed Web of Science ®Google Scholar
• Sharma R, Graham J, Mitchell H, Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009;100:707-12
   PubMed Web of Science ®Google Scholar
• Cadron I, Leunen K, Amant F, The ‘Leuven’ dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. Gynecol Oncol 2007;106:354-61
   PubMed Web of Science ®Google Scholar
• Polyzos A, Gogas H, Markopoulos C, Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes. Anticancer Res 2009;29:2851-6
   PubMed Web of Science ®Google Scholar
• See HT, Freedman RS, Kudelka AP, Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005;15:209-16
   PubMed Web of Science ®Google Scholar
• Polyzos A, Tsavaris N, Gogas H, Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel. Anticancer Res 2009;29:2681-6
   PubMed Web of Science ®Google Scholar
• Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-71
   PubMed Web of Science ®Google Scholar
• Fu S, Kavanagh JJ, Hu W, Bast RC Jr. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer 2006;16:1717-32
   PubMed Web of Science ®Google Scholar
• Garmann D, Warnecke A, Kalayda GV, Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. J Control Release 2008;131:100-6
   PubMed Web of Science ®Google Scholar
• Marques-Gallego P, den Dulk H, Brouwer J, Cytotoxic activity and cellular processing in human ovarian carcinoma cell lines of a new platinum(II) compound containing a fluorescent substituted propylene diamine ligand. Biochem Pharmacol 2009;78:365-73
   PubMed Web of Science ®Google Scholar
• Markman M, Blessing J, Rubin SC, Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006;101:436-40
   PubMed Web of Science ®Google Scholar
• Le T, Hopkins L, Baines KA, Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecol Oncol 2006;102:49-53
   PubMed Web of Science ®Google Scholar
• Hurt JD, Richardson DL, Seamon LG, Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009;115:396-400
   PubMed Web of Science ®Google Scholar
• Tinker AV, Gebski V, Fitzharris B, Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel–ANZGOG 02-01. Gynecol Oncol 2007;104:647-53
   PubMed Web of Science ®Google Scholar
• Francis P, Schneider J, Hann L, Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-8
   PubMed Web of Science ®Google Scholar
• Katsumata N, Tsunematsu R, Tanaka K, A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study. Ann Oncol 2000;11:1531-6
   PubMed Web of Science ®Google Scholar
• Markman M, Zanotti K, Webster K, Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol 2003;91:573-6
   PubMed Web of Science ®Google Scholar
• Berkenblit A, Seiden MV, Matulonis UA, A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 2004;95:624-31
   PubMed Web of Science ®Google Scholar
• Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007;25:2902-8
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis UA, Penson RT, Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6
   PubMed Web of Science ®Google Scholar
• Jurado JM, Sanchez A, Pajares B, Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 2008;10:583-6
   PubMed Web of Science ®Google Scholar
• Wright JD, Hagemann A, Rader JS, Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006;107:83-9
   PubMed Web of Science ®Google Scholar
• De Geest K, Blessing JA, Morris RT, Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2010;28:149-53
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Waggoner S, Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2005;96:67-71
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Krasner CN, Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009;27:2686-91
   PubMed Web of Science ®Google Scholar
• Vergote I, Calvert H, Kania M, A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 2009;45:1415-23
   PubMed Web of Science ®Google Scholar
• D'Agostino G, del Campo J, Mellado B, A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. Int J Gynecol Cancer 2006;16:71-6
   PubMed Web of Science ®Google Scholar
• Lee HP, Seo SS, Ryu SY, Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol 2008;109:359-63
   PubMed Web of Science ®Google Scholar
• Hasan J, Ton N, Mullamitha S, Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer 2005;93:647-51
   PubMed Web of Science ®Google Scholar
• Wagner U, du Bois A, Pfisterer J, Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy–a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 2007;105:132-7
   PubMed Web of Science ®Google Scholar
• Mangala LS, Zuzel V, Schmandt R, Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 2009;15:3770-80
   PubMed Web of Science ®Google Scholar
• Krieger ML, Eckstein N, Schneider V, Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm 2010;389:10-17
   PubMed Web of Science ®Google Scholar
• Nguewa PA, Fuertes MA, Cepeda V, Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem 2006;2:47-53
   PubMedGoogle Scholar
• Dabholkar M, Bostick-Bruton F, Weber C, ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992;84:1512-17
   PubMed Web of Science ®Google Scholar
• Sakai W, Swisher EM, Karlan BY, Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-20
   PubMed Web of Science ®Google Scholar
• Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004;10:7439-49
   PubMed Web of Science ®Google Scholar
• Nishimura S, Tsuda H, Hashiguchi Y, Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis. Int J Gynecol Cancer 2007;17:159-63
   PubMed Web of Science ®Google Scholar
• Gupta D, Owers RL, Kim M, A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol 2009;113:327-30
   PubMed Web of Science ®Google Scholar
• Polyzos A, Kosmas C, Toufexi H, Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res 2005;25:3559-64
   PubMed Web of Science ®Google Scholar
• Kavanagh JJ, Gershenson DM, Choi H, Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer 2005;15:593-600
   PubMed Web of Science ®Google Scholar
• Wolf JK, Bodurka DC, Verschraegen C, A phase II trial of oral capecitabine in patients with platinum- and taxane-refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol 2006;102:468-74
   PubMed Web of Science ®Google Scholar
• Krasner CN, McMeekin DS, Chan S, A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007;97:1618-24
   PubMed Web of Science ®Google Scholar
• Caponigro F, Willemse P, Sorio R, A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. Invest New Drugs 2005;23:85-9
   PubMed Web of Science ®Google Scholar
• Vergote I, Finkler N, del Campo J, Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 2009;45:2324-32
   PubMed Web of Science ®Google Scholar
• Pisano C, Morabito A, Sorio R, A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. Cancer Chemother Pharmacol 2009;64:1021-7
   PubMed Web of Science ®Google Scholar
• Ramirez PT, Schmeler KM, Milam MR, Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol 2008;110:56-9
   PubMed Web of Science ®Google Scholar
• Seiden MV, Gordon AN, Bodurka DC, A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol 2006;101:55-61
   PubMed Web of Science ®Google Scholar
• Coleman RL, Broaddus RR, Bodurka DC, Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006;101:126-31
   PubMed Web of Science ®Google Scholar
• Seiden MV, Burris HA, Matulonis U, A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 2007;104:727-31
   PubMed Web of Science ®Google Scholar
• Nishio S, Sugiyama T, Shouji T, Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer. Gynecol Oncol 2007;106:342-7
   PubMed Web of Science ®Google Scholar
• Gasent Blesa JM, Alberola Candel V, Provencio Pulla M, Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. Clin Transl Oncol 2009;11:35-40
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Katsumata N, Yamanaka Y, The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol 2006;100:412-16
   PubMed Web of Science ®Google Scholar
• Karaoglu A, Arslan UY, Ozkan M, Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer. Asian Pac J Cancer Prev 2009;10:63-6
   PubMed Web of Science ®Google Scholar
• Tas F, Guney N, Derin D, A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer. Int J Clin Oncol 2008;13:156-60
   PubMed Web of Science ®Google Scholar
• Ojeda Gonzalez B, Gonzalez Martin A, Bover Barcelo I, A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) Trial. Am J Clin Oncol 2008;31:481-7
   PubMed Web of Science ®Google Scholar
• Matei D, Emerson RE, Schilder J, Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 2008;113:723-32
   PubMed Web of Science ®Google Scholar
• Abushahin F, Singh DK, Lurain JR, Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol 2008;108:53-7
   PubMed Web of Science ®Google Scholar
• Karagol H, Saip P, Uygun K, The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol 2007;24:39-43
   PubMed Web of Science ®Google Scholar
• Le T, Hopkins L, Baines KA, Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer. Int J Gynecol Cancer 2008;18:428-31
   PubMed Web of Science ®Google Scholar
• Safra T, Ron I, Boaz M, Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients. Acta Oncol 2006;45:463-8
   PubMed Web of Science ®Google Scholar
• Matei D, Schilder J, Sutton G, Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol 2009;115:90-6
   PubMed Web of Science ®Google Scholar